Similarly, central cholinergic neurons undergo severe neurodegeneration in Alzheimer’s disease and agents that enhance cholinergic signaling, particularly cholinesterase inhibitor therapies, providing significant symptomatic improvement in patients with Alzheimer’s disease (Ferreira-Vieira et al., 2016; Ahmed et al., 2019). This evidence concerns the gene BCHE and Alzheimer disease.